The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2022 | Advantages and current status of off-the-shelf CAR-Ts
Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, Netherlands, gives an update on off-the-shelf chimeric antigen receptor T-cells (CAR-Ts). Manufacturing autologous CAR-Ts is a time-consuming process and access to CAR-Ts is limited. Off-the-shelf CAR-Ts represent a promising alternative to autologous CAR-T technology. However, several challenges including limited CAR-T persistence remain and need to be addressed before implementing allogeneic CAR-Ts in the clinic. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
JK is co-founder and shareholder of Gadeta and holds patents on different types of engineered immune cells and immune cell selection licensed to different commercial partners and receives revenues. JK received research support from Gadeta, Novartis, Miltenyi Biotech. For more details please visit https://www.umcutrecht.nl/en/research/researchers/kuball-jhe .
